ClinicalTrials.gg
Not yet recruitingNCT07339956Updated Jan 26, 2026

Yiwei Jiaohuang Ointment for Gastrointestinal Bleeding Associated With Oral Antithrombotic Agents

An Early Phase 1 interventional study of A Chinese herb formula--Yiwei Jiaohuang Onitment and Rabeprazole Enteric-Coated Tablets in Gastrointestinal Bleeding, sponsored by China-Japan Friendship Hospital. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2026-01-26.

Sponsored by China-Japan Friendship Hospital · Early Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Aug 2026, 3 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 90 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 40 studies in Gastrointestinal Hemorrhage with a site in China — 8 open to participants now, 9 under way, 1 of them phase 3. Gastrointestinal Hemorrhage · China.

Planned enrollment
23rd of 33
60 · median 101
Started
2026
with 1 other
Phase 1
Only one
of the 40
Registered
40th of 40
by date
Lead sponsor
1 of 40
China-Japan Friendship Hospital

Among the 40 studies in Gastrointestinal Hemorrhage with a site in China, this one is the 23rd largest by planned enrollment of the 33 interventional ones that give a count, is one of 2 that started in 2026, is the only one in phase 1, and was the 40th registered.

Gastrointestinal Hemorrhage

338 studies on the registry are indexed under Gastrointestinal Hemorrhage; 77 are open to participants now.

Browse Gastrointestinal Hemorrhage studies →

Open to participants now

8 of the 40 studies in Gastrointestinal Hemorrhage with a site in China are open now. Recruiting first, the newest first:

2 more — sign in →

All 8 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 49 Gastrointestinal Hemorrhage studies recruiting now, 39 (80%) set no upper age limit and 4 (8%) stop at 75 or younger; 3 take children under 18; 5 take healthy volunteers.

This study: 18 Years to 90 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 40 studies in Gastrointestinal Hemorrhage with a site in China, or all of them as a file.
02

Study summary

The goal of this clinical trial is to evaluate the clinical efficacy and safety of YiWei Jiaohuang Ointment in treating gastrointestinal bleeding associated with oral antithrombotic therapy. The main question it aims to answer is:

Does Yiwei JiaoHuang Ointment accelerate the conversion to negative results in fecal occult blood tests among patients with gastrointestinal bleeding associated with antithrombotic therapy? Researchers will compare use rabeprazole alone as routine therapy to see if Yiwei JiaoHuang Ointment can accelerate the conversion to negative results in fecal occult blood tests.

Participants will : Take Yiwei JiaoHuang Ointment every day for 2 weeks. Return to the hospital for a fecal occult blood test after 3 days, 1 week, and 2 weeks of medication.

03

Conditions studied

  • Gastrointestinal Bleeding

Keywords

  • Antithrombotic therapy
  • Traditional Chinese Medicine
04

Who can participate

Ages eligible
18 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Oral therapy with at least one antiplatelet or anticoagulant agent, including: aspirin, clopidogrel, ticagrelor, prasugrel, warfarin, rivaroxaban, apixaban, edoxaban, dabigatran, etc.;
  • BARC stage 1 or 2;
  • Traditional Chinese Medicine pattern identified as phlegm-heat and blood stasis obstruction syndrome;
  • Age 18-90 years;
  • Signed .

Exclusion criteria

Exclusion Criteria:

  • Patients with gastrointestinal bleeding resulting in levels \<20 g/L and/or requiring hospitalization;
  • Gastrointestinal ;
  • Cases where the source of occult blood cannot be distinguished, such as fresh bleeding from hemorrhoids;
  • Concurrent use of hemostatic traditional Chinese medicine preparations like Yunnan Baiyao;
  • Significant liver or kidney dysfunction, with , AST, or serum creatinine exceeding three times the ;
  • Pregnant women, women planning pregnancy, or lactating women;
  • Individuals deemed unsuitable for this clinical trial by the investigator.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Early Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Intervention

    Drug: A Chinese herb formula--Yiwei Jiaohuang Onitment · Drug: Rabeprazole Enteric-Coated Tablets

  • Active comparator
    Control

    Drug: Rabeprazole Enteric-Coated Tablets

Interventions

  • DrugA Chinese herb formula--Yiwei Jiaohuang Onitment

    Yiwei Jiaohuang Onitment consists of four Chinese herbs: 3g of Duyiwei(Lamiophlomis Herb), 3g of raw Da Huang(Rhubarb Root and Rhizome (Unprocessed)), 6g of Bai Ji(Bletilla Rhizome) and 10g of Ejiao (donkey-hide gelatin). Prepared as ointment, patients should take one dose daily in the morning on an empty stomach for 2 weeks.

  • DrugRabeprazole Enteric-Coated Tablets

    Rabeprazole Enteric-Coated Tablets10mg once a day for 2 weeks

06

What researchers measure

Primary outcomes

  1. The rate of negative fecal occult blood test results in the two groups of patients after 2 weeks of intervention.

    Time frame: two weeks of intervention

Secondary outcomes

  1. Time required for fecal occult blood to turn negative in two groups of patients.

    Time frame: two weeks of intervention

  2. The rate of negative fecal occult blood test results in the two groups of patients after 3 days of intervention.

    Time frame: 3 days of intervention

  3. The rate of negative fecal occult blood test results in the two groups of patients after one week of intervention.

    Time frame: one week of intervention

  4. Changes in hemoglobin levels in two groups of patients after 2 weeks of intervention.

    Time frame: two weeks of intervention

Other outcomes

  1. Changes in Gut Microbiota Before and After Treatment in Two Groups of Patients

    Time frame: two weeks of intervention

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jan 2026; primary completion for Aug 2026, 6 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 6, 2026
First posted
Jan 14, 2026
StartEst.
Jan 10, 2026
Primary completionEst.
Aug 1, 2026
CompletionEst.
Aug 30, 2026
Last update
Jan 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 26, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07339956
Responsible party
Jie, Zhang (Attending Physician, China-Japan Friendship Hospital) — Principal investigator
First posted
Jan 14, 2026
Start date
Jan 10, 2026 (estimated)
Primary completion
Aug 1, 2026 (estimated)
Completion
Aug 30, 2026 (estimated)
Last update
Jan 26, 2026

Study contacts

Jie Zhang
Contact
zhangjie9496@bucm.edu.cn
+86 15652385971

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion